Ангиозил® ретард

General characteristics. Structure:

Active agent of a trimetazidin dihydrochloride of 0,035 g,
auxiliary microcrystallic-0,1206 g of a veshchestva:tsellyuloz, gipromelloza-0,0522, silicon dioxide colloid-0,0011, magnesium stearate-0,0011 of, опадрай II (gipromelloza, lactoses monohydrate, triacetin, macrogoal, titanium dioxide, ferrous oxide yellow, ferrous oxide red)-0,008 g.

Description. Round, biconvex tablets, coated pink color.

Pharmacological properties:

Pharmacodynamics. Trimetaaidin has anti-hypoxemic effect. Directly influencing cardiomyocytes and neurons of a brain, optimiairut them to megabolia and function. the uitoprstektorny effect is caused by increase in energy potential, activation of oxidizing decarboxylation by an oxygen consumption iratsionalization (strengthening of aerobic glycolysis and blockade of oxidation of fatty acids). Maintains contractility of a myocardium, prevents intracellular exhaustion of adenosine triphosphoric acid and phosphocreatinine. In the conditions of acidosis normalizes functioning of membrane ion channels, interferes with accumulation of calcium and sodium in cardiomyocytes, normalizes intracellular concentration of potassium ions. Reduces intracellular acidosis and content of the phosphates caused by ischemia of a myocardium and reperfusion. Interferes with the damaging action of free radicals, keeps integrity of cellular membranes, prevents activation of neutrophils in an ischemia zone, increases duration of electric potential, reduces a kreatinfosfokinaza exit from cells and expressiveness of ischemic injuries of a myocardium. At stenocardia reduces the frequency of attacks (consumption of nitrates decreases), in 2 weeks of treatment tolerance to an exercise stress increases, differences of arterial pressure decrease. Improves hearing and results of vestibular tests at patients with pathology of ENT organs, reduces dizziness and a sonitus. At vascular pathology of eyes recovers functional activity of a retina of an eye.

Pharmacokinetics. After administration of drug inside триметазидин it is quickly and almost completely absorbed from digestive tract. Bioavailability - 90%. Time of achievement of the maximum concentration in a blood plasma - 5 hours. The maximum concentration after a single dose of 35 mg of a trimetazidin about 115 ng/ml. Easily gets through gistogematichesky barriers. The elimination half-life makes about 6,5 hours. Communication with proteins of a blood plasma – 16%. It is removed by kidneys (about 60% - in not changed look).

Indications to use:

- Coronary heart disease: prevention of attacks of stenocardia (in complex therapy);
- chorioretinal vascular disorders;
- cochleovestibular disturbances of the ischemic nature (sonitus, hearing disorder).

Route of administration and doses:

Ангиозил® ретард appoint on 1 tablet (35 mg) 2 times a day during meal of morning and in the evening.

Duration of therapy is established individually.

Features of use:

Drug is not intended for stopping of attacks of stenocardia. In case of development of an attack of stenocardia it is necessary to reconsider and adapt treatment.

Drug is not shown for an initial course of therapy of unstable stenocardia or a myocardial infarction.

Due to the lack of the relevant clinical data purpose of drug is not recommended to patients with heavy abnormal liver functions.

Influence on ability to control of motor transport and mechanisms
 
Ангиозил® ретард slightly influences ability to driving of transport and performance of work, demanding the increased speed of psikhomstorny reactions.

Side effects:

Frequency of the side effects noted at reception of a trimetazidin is specified in the following gradation: very often (more than 1/10), it is frequent (more than 1/100, less than 1/10), infrequently (more than 1/1000, less than 1/100), is rare (more than 1/10000, less than 1/1000), is very rare (less than 1/10000), including separate messages.
 
From the alimentary system
Often: abdominal pain, diarrhea, dyspepsia, nausea, vomiting
From the central nervous system
Often: dizziness, headache, adynamy
 Very seldom: extrapyramidal frustration (a tremor, rigidity, an akineziya), reversible after drug withdrawal.
 From integuments
Often: skin rash, itch, small tortoiseshell.
From cardiovascular system
Seldom: orthostatic hypotension, "inflows" of blood to face skin.

Interaction with other medicines:

Interaction with other medicines is not described.

Contraindications:

- hypersensitivity to any component of drug;
- deficit of lactase, lactose intolerance, syndrome glyukozo-galaktozny malabsorption;
- a renal failure (the clearance of creatinine is lower than 15 ml/min.);
- the expressed abnormal liver functions;
- pregnancy;
- breastfeeding period;
- age up to 18 years (efficiency and safety are not established).

Use at pregnancy and in the period of a lactation. Drug is contraindicated at pregnancy and in the period of a lactation.

Overdose:

Now about cases of overdose of drug it was not reported.

Storage conditions:

Period of validity - 4 years. Not to apply after the termination of the period of validity specified on packaging. In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets with the modified release, coated, 35 mg.
On 10 or 14 tablets in a blister strip packaging. On 3 or 6 blister strip packagings (on 10 tablets), or on 2 or 4 blister strip packagings (on 14 tablets) together with the application instruction in a pack from a cardboard.